Abstract
The neurobiological mechanisms of feeding involve the activity of several brain areas as well as the engagement of endogenous compounds such as ghrelin, melanin-concentrating hormone, orexin, neuropeptide Y, leptin, vasoactive intestinal peptide, cholecystokinin, among others. Furthermore, the family of food-intake modulators has been enlarged due to the inclusion of lipids such as N-arachidonoylethanolamide (anandamide), as well as oleoylethanolamide (OEA). In this regard, the food-intake suppressing properties of OEA have been described since pharmacological administration of this compound induces anorexia. It has been suggested that satiety induced by OEA may be through the activation of peroxisome proliferator-activated receptor-α (PPAR-α), a ligand-activated transcription factor that modulates several pathways of lipid metabolism. The mechanism of action of OEA remains unknown, it has been suggested that the ingestion of dietary fat stimulates epithelial cells of the small intestine and promotes the synthesis and release of OEA. Upon its release, this lipid acts within the gut engaging sensory fibers of the vagus nerve to diminish food-intake. Here, recent advances in our understanding of the neurobiological role of OEA in modulation of feeding will be reviewed. Also, we highlight the emerging molecular mechanism of anorexia induced by OEA.
Keywords: Anorexia, central nervous system, endocannabinoids, feeding, hypothalamus
Central Nervous System Agents in Medicinal Chemistry
Title:Brain Molecules and Appetite: The Case of Oleoylethanolamide
Volume: 13 Issue: 1
Author(s): Andrea Sarro-Ramirez, Daniel Sanchez-Lopez, Alma Tejeda-Padron, Carmen Frias, Jaime Zaldivar- Rae and Eric Murillo-Rodriguez
Affiliation:
Keywords: Anorexia, central nervous system, endocannabinoids, feeding, hypothalamus
Abstract: The neurobiological mechanisms of feeding involve the activity of several brain areas as well as the engagement of endogenous compounds such as ghrelin, melanin-concentrating hormone, orexin, neuropeptide Y, leptin, vasoactive intestinal peptide, cholecystokinin, among others. Furthermore, the family of food-intake modulators has been enlarged due to the inclusion of lipids such as N-arachidonoylethanolamide (anandamide), as well as oleoylethanolamide (OEA). In this regard, the food-intake suppressing properties of OEA have been described since pharmacological administration of this compound induces anorexia. It has been suggested that satiety induced by OEA may be through the activation of peroxisome proliferator-activated receptor-α (PPAR-α), a ligand-activated transcription factor that modulates several pathways of lipid metabolism. The mechanism of action of OEA remains unknown, it has been suggested that the ingestion of dietary fat stimulates epithelial cells of the small intestine and promotes the synthesis and release of OEA. Upon its release, this lipid acts within the gut engaging sensory fibers of the vagus nerve to diminish food-intake. Here, recent advances in our understanding of the neurobiological role of OEA in modulation of feeding will be reviewed. Also, we highlight the emerging molecular mechanism of anorexia induced by OEA.
Export Options
About this article
Cite this article as:
Sarro-Ramirez Andrea, Sanchez-Lopez Daniel, Tejeda-Padron Alma, Frias Carmen, Zaldivar- Rae Jaime and Murillo-Rodriguez Eric, Brain Molecules and Appetite: The Case of Oleoylethanolamide, Central Nervous System Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871524911313010010
DOI https://dx.doi.org/10.2174/1871524911313010010 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets “Speed” Warps Time: Methamphetamines Interactive Roles in Drug Abuse, Habit Formation, and the Biological Clocks of Circadian and Interval Timing
Current Drug Abuse Reviews Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Omalizumab in Children with Severe Allergic Asthma: The Italian Real- Life Experience
Current Respiratory Medicine Reviews Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine
Current Pharmaceutical Design Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate
Recent Patents on Inflammation & Allergy Drug Discovery Metabolic Cooperation in Testis as a Pharmacological Target: From Disease to Contraception
Current Molecular Pharmacology Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes
Current Medicinal Chemistry